BioTuesdays

Category - Markets

Echelon starts Medical Facilities at buy

Echelon Wealth Partners initiated coverage of Medical Facilities (TSX:DR) with a “buy” rating and one-year price target of $22.50. The stock closed at $21.50 on Monday.Medical Facilities (MFC) is a physician-owned...

Maxim cuts Sucampo Pharma price target to $17

Maxim Group lowered its price target for Sucampo Pharmaceuticals (NASDAQ:SCMP) to $17 from $26, citing a combination of the market environment and an assessment of the catalysts and risks. The stock was quoted at $11.89...

Maxim cuts Galmed Pharma price target to $9

Maxim Group lowered its price target for Galmed Pharmaceuticals (NASDAQ:GLMD) to $9 from $24, citing a bearish biotech market environment, catalysts, and revisions to timelines, as well as other related assumptions. The...

HCW cuts Seres Therapeutics price target to $15

H.C. Wainwright lowered its price target for Seres Therapeutics (NASDAQ:MCRB) to $15 from $50 after disappointing Phase 2 results in patients with recurrent C. difficile infection (CDI). The stock was quoted at $9...

Maxim cuts Stellar Biotechnologies price target to $7

Maxim Group lowered its price target for Stellar Biotechnologies (NASDAQ:SBOT) to $7 from $17, citing market environment, catalysts related to clients for Stellar’s Keyhole Limpet Hemocyanin (KLH) protein, revisions to...

Maxim downgrades Keryx Biopharmaceuticals to hold

Maxim Group downgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “hold” from “buy” and removed its price target for the stock, which was quoted at $5.16, down $2.20, or 30% in trading Monday afternoon.The move reflected...

Feltl upgrades Novadaq to strong buy

Feltl & Co. upgraded Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) to “strong buy” from “buy” after the company posted second quarter revenue ahead of expectations yesterday on the strength of its direct sales...

Novadaq Q2 revenue climbs 34%

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) reported revenue of $20.1-million in the second quarter, an increase of 34% from $15.1-million a year ago.Total direct sales in the latest quarter increased by $4.4-million...

BTIG downgrades NeoGenomics to neutral

BTIG Research downgraded NeoGenomics (NASDAQ:NEO) to “neutral” from “buy.” The stock closed at $9.05 on Tuesday.Analyst Dr. Sean Lavin writes that second quarter results were largely in-line. “The base business...

Roth cuts GenVec price target to $2

Roth Capital Partners lowered its price target for “buy-rated” GenVec (NASDAQ:GNVC) to $2 from $8, even though the FDA lifted the clinical hold on CGF166, being run worldwide by partner Novartis. The stock closed at 60...

Subscribe

Sign up to our weekly BioTuesdays newsletter.